Atossa Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview

Atossa Therapeutics

09/08/2024 19:35

* Atossa Therapeutics Inc  ATOS.OQ   ATOS.O  is expected
to show
no change in quarterly revenue when it reports  results on
August 12 (estimated) for the period ending January 1 0001
    * 
    * ​LSEG's mean analyst estimate for Atossa Therapeutics Inc
is for
a loss of 6 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Atossa
Therapeutics Inc is $6.00​, above​ its last closing price
of $1.20. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.07       -0.07      -0.05     Beat    25
 Dec. 31 2024  -0.05       -0.06      -0.09     Missed  -58.8
 Sep. 30 2023  -0.07       -0.07      -0.05     Beat    28.6​
 Jun. 30 2023              -0.06      -0.08     Missed  -33.3
 ​​Mar.                    -0.06      -0.05     Beat    16.7
 31 2023                                                
 Dec. 31 2022              -0.06      -0.06     Met     0​
 Sep. 30 2022              -0.06      -0.06     Met     0
 Jun. 30 2022              -0.06      -0.05     Beat    16.7
 This summary was machine generated August 9 at 18:34 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)